Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. Athersys, Inc.
  6. Notizie
  7. Altre lingue
    ATHX   US04744L2051

ATHERSYS, INC.

(ATHX)
  Rapporto
Tempo differito Nasdaq  -  21:42:04 03/02/2023
1.710 USD   +6.88%
09/01Athersys, Inc. fornisce un aggiornamento sugli studi clinici in corso con MultiStem per il trattamento dei pazienti dopo un trauma emorragico (MATRICS-1) e per il trattamento dell'ictus ischemico (MASTERS-2)
CI
05/01Athersys, Inc. nomina Joseph Nolan nel suo Consiglio di Amministrazione
CI
2022Transcript : Athersys, Inc., Q3 2022 Earnings Call, Nov 15, 2022
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su ATHERSYS, INC.
02/02Athersys to Host Business Update Conference Call on February 14th
30/01Athersys to Participate in International Stroke Conference and BioProcess International
25/01Athersys, Inc / New: Other Events (form 8-K)
11/01Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit..
09/01Athersys Provides MultiStem Clinical Update
09/01Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Tre..
05/01Athersys, Inc / New: Change in Directors or Principal Officers (form 8-K)
05/01Athersys Appoints Joseph Nolan to Its Board of Directors
05/01Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors
2022Athersys, Inc / New: Notice of Delisting or Failure to Satisfy a Continued Listing Rule o..
2022Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
2022ATHERSYS, INC / NEW Management's Discussion and Analysis of Financial Condition and Re..
2022Athersys, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
2022Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital ..
2022Athersys Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
2022Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital ..
2022Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offerin..
2022Athersys: Securities Purchase Agreement - Form 8-K
2022Athersys, Inc / New: Entry into a Material Definitive Agreement, Other Events, Financial ..
2022Athersys Reschedules Third Quarter Conference Call to November 15
2022Athersys Prices $5.5 Million Public Offering; Shares Slump
2022Athersys, Inc. Announces Pricing of $5.5 Million Public Offering
2022Sector Update: Health Care Stocks Advance During Tuesday Trading
2022Sector Update: Health Care Receiving Strong Support Again on Tuesday
2022Top Premarket Decliners
2022US Futures Move Cautiously Higher as American Head to Polls for Midterms
2022Athersys, Inc. Announces Proposed Public Offering
2022Athersys Announces Public Offering Plan
2022Athersys, Inc / New: Change in Directors or Principal Officers (form 8-K)
2022Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directo..
2022Scynexis Names Ivor Macleod CFO
2022Athersys to Host Third Quarter Financial Results Call
2022Athersys, Inc / New: Notice of Delisting or Failure to Satisfy a Continued Listing Rule o..
2022Athersys to Present at 2022 Cell and Gene Meeting on the Mesa Conference and Attend 14t..
2022Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th ..
2022Athersys to Host Business Update Conference Call on October 6th
2022Athersys to Host Business Update Conference Call on October 6th
2022Sector Update: Health Care Stocks Paring Losses in Late Uptick
2022Sector Update: Health Care
2022Top Midday Gainers
2022Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Dire..
2022Athersys, Inc / New: Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
2022Athersys, Inc.(NasdaqCM:ATHX) dropped from S&P Global BMI Index
2022Athersys: Current Report - Form 8-K
2022Athersys, Inc / New: Other Events (form 8-K)
2022Athersys, Inc / New: Other Events (form 8-K)
2022Athersys, Inc / New: Material Modification to Rights of Security Holders, Amendments to A..
2022Wall Street Set to Open Higher Ahead of Powell's Outlook in Jackson Hole
2022US Futures Lower Ahead of Fed Chair Powell's Outlook
2022Top Premarket Decliners
2022Athersys to Launch 1-for-25 Reverse Stock Split; Shares Drop
2022Athersys Announces 1-for-25 Reverse Stock Split
2022Athersys Raises $12 Million From Registered Direct Offering of Common Stock, Warrants
2022Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering
2022Athersys, Inc / New: Entry into a Material Definitive Agreement, Financial Statements and..
2022Athersys: Securities Purchase Agreement - Form 8-K
2022Athersys Signs $12 Million Registered Direct Offering
2022Athersys, Inc. Announces $12 Million Registered Direct Offering
2022ATHERSYS, INC / NEW Management's Discussion and Analysis of Financial Condition and Re..
2022Athersys: REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - Fo..
2022Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update
2022Earnings Flash (ATHX) ATHERSYS Posts Q2 Revenue $2.3M
2022Athersys, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2022
2022Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense De..
2022Athersys, Inc. Announces Favorable Preclinical Results for MultiStem Treatment in Defen..
2022Athersys, Inc / New: Change in Directors or Principal Officers (form 8-K)
2022Athersys Appoints Kasey Rosado as Interim Chief Financial Officer
2022Athersys, Inc. Appoints Kasey Rosado as Interim Chief Financial Officer
2022Athersys, Inc / New: Change in Directors or Principal Officers, Submission of Matters to ..
2022Athersys to Host Second Quarter Financial Results Call
2022Athersys Says Equity Purchase Deal With Aspire Capital Fund Has Been Terminated
2022Athersys: Termination of a Material Definitive Agreement - Form 8-K
2022Athersys, Inc / New: Termination of a Material Definitive Agreement, Change in Directors ..
2022Athersys and Aspire Capital Fund Terminate Relationship
2022Athersys, Inc. Designates Dan Camardo as the Principal Financial Officer and Principal ..
2022Athersys, Inc. cancelled the transaction announced on May 12, 2022
2022Athersys, Inc / New: Change in Directors or Principal Officers (form 8-K)
2022Athersys, Inc. Announces Board Changes
2022Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and..
2022Wall Street Set to Open Higher
2022US Futures Move Higher Friday
2022Top Premarket Gainers
2022Athersys: POSTPONES ANNUAL MEETING OF STOCKHOLDERS - Form 8-K
2022Athersys, Inc / New: Shareholder Director Nominations, Other Events, Financial Statements..
2022Athersys Postpones Annual Meeting of Stockholders
2022Athersys Hosting KOL Panel Event to Discuss TREASURE Data
2022Athersys Reducing Workforce by 70% to Cut Costs -- Shares Fall 7% After-Hours
2022Athersys: ANNOUNCES THAT ITS PARTNER, HEALIOS K.K., REPORTED TOPLINE DATA FROM THE TREASU..
2022Athersys, Inc / New: Costs Associated with Exit or Disposal Activities, Change in Directo..
2022Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinic..
2022Athersys, Inc. Announces Resignation of Ivor Macleod as Chief Financial Officer, Effect..
2022Athersys, Inc. Announces Management Changes
2022Top Midday Decliners
2022Athersys Shares Drop After BofA Securities Downgrade
2022Athersys Shares Tumble Pre-Bell as MultiStem Study Misses Primary Endpoint
2022Top Premarket Decliners
2022Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREAS..
2022Athersys to Participate in the H.C. Wainwright Global Investment Conference
2022Athersys, Inc / New: Entry into a Material Definitive Agreement, Financial Statements and..
2022Athersys, Inc. announced that it expects to receive $100 million in funding from Aspire..